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Background: Despite advances in diagnostic and treatment strategies, head and neck squamous cell cancer
(HNSCC) constitutes one of the worst cancer types in terms of prognosis. PTEN is one of the tumour suppressors
whose expression and/or activity have been found to be reduced in HNSCC, with rather low rates of mutations
within the PTEN gene (6-8%). We reasoned that low expression levels of PTEN might be due to a transcriptional
repression governed by an oncogene. Tbx2 and Tbx3, both of which are transcriptional repressors, have been
found to be amplified or over-expressed in various cancer types. Thus, we hypothesize that Tbx3 may be over
expressed in HNSCC and may repress PTEN, thus leading to cancer formation and/or progression.
Methods: Using immunohistochemistry and quantitative PCR (qPCR), protein and mRNA levels of PTEN and Tbx3
were identified in samples excised from cancerous and adjacent normal tissues from 33 patients who were
diagnosed with HNSCC. In addition, HeLa and HEK cell lines were transfected with a Tbx3 expressing plasmid and
endogenous PTEN mRNA and protein levels were determined via qPCR and flow cytometry. Transcription assays
were performed to demonstrate effects of Tbx3 on PTEN promoter activity. Mann–Whitney, Spearman’s Correlation
and Wilcoxon signed-rank tests were used to analyze the data.
Results: We demonstrate that in HNSCC samples, Tbx3 mRNA levels are increased with respect to their normal
tissue counterparts (p<0.001), whereas PTEN mRNA levels are significantly reduced in cancer tissues. Moreover, Tbx3
protein is also increased in HNSCC tissue sections. Over-expression of Tbx3 in HeLa and HEK cell lines causes
reduction in endogenous PTEN mRNA and protein levels. In addition, transcription activity assays reveal that Tbx3 is
capable of repressing both the basal and induced promoter activity of PTEN.
Conclusions: We show that Tbx3 is up-regulated in tissue samples of HNSCC patients and that Tbx3 represses
PTEN transcription. Thus, our data not only reveals a new mechanism that may be important in cancer formation,
but also suggests that Tbx3 can be used as a potential biomarker in cancer.
Keywords: Tbx3, PTEN, Cancer, Squamous cell carcinomaBackground
The T-box is a conserved DNA-binding and
dimerization motif, which was first identified in the
mouse protein Brachyury [1] and the genes encoding T-
box containing proteins are collectively known as the T-
box (TBX) family of genes. Tbx transcription factors
family plays important roles in cell proliferation, fate
and identity during development [2,3]. Based on their* Correspondence: yavuzer@akdeniz.edu.tr
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reproduction in any medium, provided the orsequence similarities, five subfamilies have been identi-
fied in mouse and the Tbx2 subfamily is comprised of
Tbx2, Tbx3, Tbx4 and Tbx5 [4]. Through their T-box
domains, each T-box factor binds to the “T-half-site”
found in the promoters of the target genes and regulates
gene expression by either activating or repressing tran-
scription. Amongst the Tbx family of proteins, Tbx3 and
Tbx2 are known to function generally as transcriptional
repressors, although Tbx3 has also been shown to have
an activation domain [5-7]. In humans, TBX3 mutations
cause ulnar-mammary syndrome (UMS) which is char-
acterized by mammary gland hypoplasia, abnormal limbl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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genitalia [8]. In addition to its key role in development,
TBX3 expression has also been found to be amplified or
over-expressed in many different cancer types including
breast, cervix, ovary, pancreas, liver cancers and melano-
mas [9-14]. Research towards identifying the molecular
mechanisms of Tbx3 in cancer formation revealed that
Tbx3 interacts with proteins of several oncogenic path-
ways. In liver tumorigenesis for example, Tbx3 lies
downstream of the Wnt-β-catenin pathway and is a
regulator of β-catenin [12]. Tbx3 also represses E-
cadherin which has been implicated in metastasis of epi-
thelial tumours [13]. In breast cancer, FGF signalling
regulates Tbx3 [15] and Tbx3 cooperates with c-Myc
and Ras associated transformation [16,17]. Another well-
defined pathway that Tbx3 takes part is the p14/19ARF-
Mdm2-p53 pathway. Tbx3 represses the expression of
the human tumour suppressor gene p14ARF and the
murine homolog p19ARF [17-19]. In addition, Tbx3 dir-
ectly represses the p21Cip1/WAF1 promoter [20]. The p14/
19ARF-Mdm2-p53 pathway plays an important role in
regulating cell senescence and protects the cells against
oncogenic transformation. Repression of p14/19ARF or
p21Cip1/WAF1 by Tbx3 seems to block this protective
pathway and bypass cellular senescence via p53
dependent or independent ways, thus leading to uncon-
trolled cell proliferation. In the light of the available evi-
dence, it seems that Tbx3 uses multiple pathways and
mechanisms in driving tumorigenesis.
Head and Neck cancers originate on the mucosal sur-
faces of oral cavity, pharynx and larynx. Because 90% of
these malignancies exhibit squamous cell characteristics,
the head and neck cancers are commonly called “Head
and Neck Squamous Cell Carcinomas” (HNSCC).
Worldwide, HNSCC is the sixth most common cancer
type, with extremely poor clinical outcomes [21,22]. Re-
search during the last decade revealed some of the mo-
lecular mechanisms underlying the pathogenesis of
HNSCC. Inactivation of many tumour suppressor gene
products such as p53, p16INK4a, E-cadherin and PTEN
[23-27] or activation of proto-oncogenes such as Cyclin
D, EGFR and p63 [28-30] have been found to be impli-
cated in HNSCC occurrence.
The gene phosphatase and TENsin Homolog (PTEN)
encodes a tumour suppressor which is mostly inactivated in
many cancers. PTEN is the main negative regulator of the
phosohatidylinositol-3-Kinase (PI3K) signalling pathway.
PI3 kinases that are activated by either receptor tyrosine
kinases (RTK) or G-protein coupled receptors (GPCR),
catalyze conversion of phosohatidylinositol 4,5 phosphate
(PIP2) to phosohatidylinositol 3,4,5 phosphate (PIP3),
thereby activate AKT kinase and subsequent downstream
components [31]. PTEN is a lipid and protein phosphatase
and inhibits PI3K mediated signals involved in cellulargrowth, proliferation and survival by dephosphorylating
PIP3 at the plasma membrane [32]. Although PTEN was
found to be down-regulated in many different cancer types,
this is not necessarily due to somatic mutations of the
PTEN gene. Indeed, in a group of HNSCC tumour samples,
it was demonstrated that down-regulation of PTEN was
not due to its allelic loss or point mutations within the gene
[26,27], indicating that the reduced expression of PTEN
might be as a consequence of either transcriptional or post-
transcriptional regulations.
The role of Tbx3 in regulation of pathways involved in
cell proliferation, especially tumour suppressors such as
E-cadherin and p53, which have also been found to be
inactivated in HNSCC, prompted us to analyze the Tbx3
status in this particular type of cancer. To this end, in a
period of 2 years, tissue samples were collected from
patients undergoing operation with the diagnosis of
HNSCC. During operations, samples were excised from
both the seemingly cancerous areas and also from the
normal-looking tissue surrounding the lesion site. Both
kind of tissues (cancer and normal) were examined
pathologically and then analyzed for expression of Tbx3
mRNA and protein levels. In addition, PTEN mRNA
was also measured as it has been shown to be down-
regulated in most of the samples of HNSCC. In this
paper we report that in HNSCC samples both the
mRNA and protein levels of Tbx3 are increased with re-
spect to their normal tissue counterparts, whereas PTEN
mRNA levels are decreased in cancer tissues as it has
been reported before [33]. We also demonstrate that in
two different cell lines, over expression of Tbx3 causes
reduction in endogenous PTEN mRNA and protein
levels. In addition, using transcription activity assays we
show that Tbx3 is capable of repressing both the basal
and induced promoter activity of PTEN.
Methods
Tissue samples
In a two-year period, surgical resection specimens from
33 patients who underwent partial or total laryngectomy
for HNSCC in the Ear-Nose and Throat Head and Neck
Surgery Department of Akdeniz University, School of
Medicine, were collected. In compliance with the princi-
ples of the Declaration of Helsinki, the study was
approved by the Ethical Committee of the University
(No: 04.12.09/011398) and written informed consents
were obtained from patients who accepted to participate
in the study. During operation, samples were collected
from both the cancerous area and the adjacent normal
tissues. Before sending the tissues for pathological exam-
ination, about 10 mg from each of the tissue (cancer and
normal) was spared and immediately placed in RNAlater
TissueProtect Tubes (Qiagen GmbH, Cat No: 76163) to
prevent degradation of RNA. The specimens were
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University. Following routine paraffin embedding, sec-
tions in 5μm thicknesses were prepared and stained with
haematoxylin/eosin (H&E) for histopathological evalu-
ation. Pathological features of the patients were exam-
ined according to the American Joint Committee on
Cancer (AJCC) [34]. Upon confirmation of tissues as
cancerous and normal, the samples that were spared for
RNA analyses were sent to the Physiology Department
and stored at -80°C till usage.
RNA analysis
Frozen tissues were disrupted and homogenized by MagNa
Lyser Instrument (Roche, GmbH) and total RNA was iso-
lated by using RNeasy Mini Kit (Qiagen GmbH, Cat No:
74124) according to the manufacturer’s instructions. RNA
(1μg) was then reverse transcribed using the Transcriptor
High Fidelity cDNA synthesis kit according to the manufac-
turer’s instructions (Roche GmbH, Cat No: 508195500).
For real-time PCR, LightCycler 1.5 Instrument was used.
The primer pairs for amplification of Tbx3 [GenBank:
NM_005996.3], PTEN [GenBank: NM_000314.4] and
human β-actin [GenBank:NM_001101.3] were designed
using the Universal Probe Library (UPL) Assay Design Cen-
ter (www.roche-applied-science.com). The human β-actin
gene was used as an internal standard to correct sample-to-
sample variations within a PCR run. Hydrolysis (TaqMan)
probes; Probe 47 (Roche GmbH, Cat no: 04688074001),
Probe 48 (Roche GmbH, Cat no: 04688082001) and Probe
64 (Roche GmbH, Cat no: 04688635001) from the UPL
were used for detection and quantification of Tbx3, PTEN
and human β-actin mRNAs. The cDNA from each gene
was amplified by PCR using the appropriate primer sets
and probes with the TaqMan Master Mix (Roche GmbH,
Cat No: 04735536001) according to the manufacturer’s
instructions. The data was analyzed using the analysis mod-
ule for absolute quantification of LightCycler Software 4.1.
Construction of the PTEN promoter reporter plasmids
The PTEN promoter region [GenBank No: AF067844.1]
between positions −1895 to + 400 (Extended promoter –
EP-PTEN) was amplified from genomic DNA by PCR
using the primers (F1) 50-agacagatctGTGGGGTGCG
GGGTAGGAGT and (R1) 50-agacaagcttGACGAAG
AGGAGGCGAGA. For the amplification of the core
promoter region (CP-PTEN) lying between −1477 and
−710, the primer pair (F2) 50-agacagatctGGCTTGCT
CTTAGGGTAG and (R2).
50-gcgtaagcttCGTGAACACATAGCCGT was used. The
deletion mutant (Δmut CP-PTEN) between positions −1345
and −710 was amplified from genomic DNA via PCR using
the F3 (50- agacagatctCCAGTTCCCCAAGCGCCAG) and
R2 primer pair. The sequences in lowercase are present to
facilitate cloning by placing Bgl II and Hind III restrictionenzyme recognition sequences (depicted in bold and
underlined). The EP-PTEN (2295 bp), the CP-PTEN (767
bp) and the Δmut CP-PTEN (635 bp) PCR products were
digested by Bgl II/ HindIII and cloned into a pGL3.1-Basic
plasmid (Promega), which was linearized using the same
restriction endonucleases. All constructs were verified by
DNA sequencing. The Tbx3 and USF expression plasmids
were kindly provided by Prof. Colin R. Goding (Ludwig
Institute for Cancer Research, Oxford, UK).
Cell culture and transcriptional activity assays
The HeLa and HEK cell lines were used for transcriptional
activity assays as these cell lines are well known for being
easy to grow and readily transfectable. In addition both
cell lines express PTEN and do not contain genetic muta-
tions of p53. The cell lines were maintained at 370C with
5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% fetal calf serum (FCS) and 1%
penicillin/streptomycin. Cells were plated on 96-well
dishes and co-transfected with 0.5μg/well PTEN pGL3.1
reporter plasmids and Tbx3 and/or USF expression plas-
mids (0.2 to1.0 μg/well) using FuGene HD (Roche, Cat no:
04709691001) according to the manufacturer’s instruc-
tions. After 48 hours, cells were harvested and lysed by
using the One-Glo Luciferase Assay System (Promega,
Cat no:E6110). The lysates were then analyzed on a lumin-
ometer (Luminoskan Ascent, ThermoScientific). The
experiments were repeated at least five times before estab-
lishing the final data. For each construct, values from 5
different experiments were obtained; average values were
calculated and the data was presented as “% Promoter Ac-
tivity” relative to the promoter activity of CP-PTEN
(100%). Flow cytometry and western blots were performed
in parallel to confirm the basal and over-expressed Tbx3
protein levels for each experiment and one representative
western blot was shown in the relevant figures. To meas-
ure the endogenous PTEN mRNA levels, HeLa and HEK
cell lines were transfected with a Tbx3 expressing plasmid
in different concentrations and cells were harvested 48
hours following transfection. From transfected and
untransfected cell lines, RNA was isolated and quantitative
reverse transcription-polymerase chain reaction (qRT-
PCR) was performed as described above. For endogenous
PTEN protein determination, both of the cell lines were
seeded onto 6-well dishes and transfected with Tbx3
expressing plasmid as described before. Forty-eight hours
following transfection, cells were harvested and flow cyto-
metry was performed as mentioned below.
Immunohistochemistry and immunoblots
Parafin embedded, 5μm thick tissue sections were stained
for Tbx3 protein using a monoclonal anti-Tbx3 antibody
(ABCAM, Cat no: ab89220). The sections were analysed
using standard avidin-biotin immunohistochemical
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(Vector Laboratories, Burlingane, California). An anti
IgG-antibody was used as control.
For immunoblots; transfected and untransfected cells
were harvested and lysed in lysis buffer (150 mM NaCl, 50
mM Tris pH 8.0, 1.0 % NP40) and the protein content
was determined by Bradford method. Equal amounts of
protein was loaded onto 10% SDS-PAGE and separated by
electrophoresis (80V, 2hr). This was followed by blotting
onto nitrocellulose membranes. Immunoblotting was per-
formed using anti-Tbx3 antibody at a dilution of 1:100.
Immunoreactive bands were revealed by an ECL kit
(Amersham) according to the manufacturer’s instructions.Flow cytometry
Transfected and untransfected cell lines were harvested
and washed twice with phosphate buffered saline
(PBS). BD Biosciences Cytofix/CytopermTM Kit (CatFigure 1 Tbx3 mRNA and protein levels are increased in HNSCC tissu
from patients who were diagnosed with HNSCC. RNA was isolated and mR
probes. Results were normalized to β-Actin mRNA levels. The sign “*”denot
normal tissue mRNA levels (p<0.001). (C) Laryngeal squamous cell carcinom
anti-IgG antibody (b) as an isotypic control. Squamous cell carcinoma secti
anti-Tbx3 antibody with respect to the normal epithelium (d) (magnificationo: 554714) was used for fixation and permeabilization
of cells according to manufacturer’s instructions. Cells
were incubated for 30 min. at room temperature with
anti-Tbx3 (ABCAM, Cat no: ab89220) and anti-PTEN
(BD™ Phosflow 560002, labelled with PE-A) antibodies
simultaneously, which were diluted in BD Biosciences
Perm/Wash Buffer in 1:50 and 1:10 ratios, respectively.
Following the washing steps, cells were incubated with
a secondary antibody (DyLight 488, ABCAM, Cat no:
ab96879) at a dilution of 1:2000 to enable detection of
Tbx3. Analyses were performed on a BD FACS Canto
II and protein expression of both Tbx3 and PTEN
were measured in a total of 10,000 cells.Statistical analysis
The Statistical Package for the Social Sciences (SPSS)
18.0 software was used. Comparison of the mRNA levels
between the tumour and normal tissues were performedes. Tissues from cancerous and adjacent normal areas were excised
NA levels of Tbx3 (A) and PTEN (B) were quantified using TaqMan
es for statistically significant increase and decrease with respect to the
a tissue sections stained with haemotoxcylin/eosin (HE) (a) and
ons (c) exhibited stronger cytoplasmic and nuclear staining with
n 100x).
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ation test was used for evaluation of PTEN mRNA levels
in response to over-expressed Tbx3. Mann–Whitney test
was employed for interpretation of the in vitro transcrip-
tional activity assays. Data are means of ±SDs of five in-
dependent experiments and p<0.05 was considered
statistically significant.
Results
Tbx3 mRNA and protein expression is increased in HNSCC
A total of 33 patients (32 males and 1 female), with a
median age of 53 years, were analyzed. The majority of
patients (85%) had HNSCC originated from larynx
(n=28), 6% from tongue (n=2) and in 3 patients from
oropharynx, submandibular gland or tonsils (3% each).
The clinical stage was IV in 73% of patients, whereas
27% of patients were at stage III. In the sample group
only one patient was at stage II. The mRNA expression
of Tbx3 was found to be significantly increased in cancer
samples (min-max: 22–7100, median: 242) with respect
to the normal tissue (min-max: 12–1460, median: 5.38)
obtained from the same individuals (p<0.001)
(Figure 1A). Although generally PTEN mRNA expres-
sion was rather low in tissues, still there was a statisti-
cally significant reduction in expression in cancer tissues
(min-max: 0–5.62, median: 0.0085) when compared to
the normal tissue (min-max: 0–13.10, median: 0.5,
p<0.001) (Figure 1B). Neither the clinical stage nor the
origin of cancer exhibited a statistically significant differ-
ence in Tbx3 mRNA levels. In order to determine
whether the increase in Tbx3 mRNA level correlates
with protein level in HNSCC tissue samples, paraffin
embedded cancer and normal tissue sections were
stained with anti-Tbx3 antibody. As seen in Figure 1C,
tumour sections (c) exhibited significantly stronger cyto-
plasmic and nuclear Tbx3 staining with respect to the
normal tissues (d). We were not able to detect PTEN
protein in HNSCC tissue samples, possibly due to low
levels of PTEN mRNA in these tissues. As a conse-
quence western blotting was not sensitive enough to de-
tect such small amounts of protein. Nevertheless, these
results demonstrated for the first time that both mRNA
and protein levels of Tbx3 are increased in HNSCC tis-
sue samples.
Endogenous PTEN mRNA and protein levels are reduced
in response to Tbx3 expression
The inverse correlation of Tbx3 and PTEN mRNA levels
in HNSCC samples prompted us to analyze whether
Tbx3 would cause a reduction in endogenous PTEN
mRNA levels. To this end, HeLa and HEK cell lines
were used as both of these cell lines are known to ex-
press PTEN and relatively low levels of Tbx3. The cell
lines were transfected with a plasmid carrying a cDNAthat expresses Tbx3. Three different plasmid DNA con-
centrations (as measured by a spectrophotometer) were
used in transfections (0.2, 0.5 and 1 μg). Forty-eight
hours following transfection, RNA was isolated from the
transfected and untransfected cells and PTEN mRNA
levels were quantified using TaqMan probes. As seen in
Figure 2A, transfection of a Tbx3 expressing plasmid in
increasing amounts caused a gradual decrease in PTEN
mRNA levels in both of the cell lines. Spearman’s Cor-
relation test revealed a significant negative correlation
between the amounts of transfected Tbx3 expression
plasmid and PTEN mRNA levels (r = −0,858 and
p<0.05). In order to verify that transfection of a Tbx3
expressing plasmid causes over expression of Tbx3 pro-
tein in the cells, flow cytometry was employed. In
addition, using a differentially labelled (PE-A) anti-
PTEN antibody, PTEN protein levels were analysed in
the same cell lines to determine whether over-expressed
Tbx3 protein affects the PTEN protein level. In untrans-
fected cells endogenous Tbx3 and PTEN levels were ra-
ther low (Figure 2B, panels a and c). Transfection of 1
μg of Tbx3 expressing plasmid caused an increase in
Tbx3 protein levels (b) with respect to untransfected
cells (a), demonstrating that Tbx3 protein was over-
expressed in transfected cell lines (Figure 2B, panels a
and b). Interestingly, cells transfected with a Tbx3
expressing plasmid displayed a reduction in PTEN pro-
tein levels with respect to the untransfected cells
(Figure 2B, panels d and c, respectively). Thus, these
results indicate that transfection of a Tbx3 expressing
plasmid causes over expression of Tbx3 protein within
the cells and the over-expressed Tbx3 protein results in
reduction of both endogenous mRNA and protein levels
of PTEN.
Tbx3 Represses PTEN promoter activity
The schematic diagram of the PTEN promoter region is
given in Figure 3A. The analysis of the PTEN promoter
[GenBank: AF067844.1] revealed that PTEN has a TATA-
less and GC-rich promoter. The start codon (ATG) is pre-
ceded by a 1030 bp long leader sequence within the first
exon. The core promoter of PTEN lies between positions
−1344 to −745 with respect to the beginning of the first
exon (0) [35]. This region contains binding sites for tran-
scription factors USF, Sp1 and EGR1 and has been shown
to govern maximum promoter activity [36-38]. The min-
imal promoter is also localized within this region between
positions −958 to −821. In order to assess the role of Tbx3
in regulation of PTEN transcription, the PTEN promoter
region between positions −1895 to +400 (EP-PTEN) and
also a smaller region between −1477 and −710, encom-
passing the core promoter, were cloned into a luciferase
reporter plasmid (CP-PTEN) (Figure 3B). Thus, the CP-
PTEN encompassing the core promoter region extends
Figure 2 Tbx3 represses endogenous PTEN mRNA levels. (A) Different amounts of plasmid DNA (0.2, 0.5 and 1.0 μg) that expresses Tbx3 was
transfected into HeLa and HEK cell lines. RNA from untransfected and transfected cell lines was isolated and PTEN mRNA levels were determined
using TaqMan probes. Results were normalized to β-Actin mRNA levels. Spearman’s Correlation test revealed a significant decrease in PTEN mRNA
levels with increasing amounts of Tbx3 expressing plasmid (r= −0.858 and p<0.05). (B) Cells transfected with 1μg of Tbx3 expressing plasmid and
untransfected cells were analysed by flow cytometry using differentially labelled antibodies against Tbx3 (Labelled with DyLight 488) and PTEN
(labelled with PE-A) for determination of Tbx3 and PTEN protein levels. Left panels (untransfected cells, a and c) display the endogenous Tbx3
and PTEN protein levels, which are shown in P6 and P3, respectively. Upon transfection, Tbx3 protein is increased (b) within the cells. In cells,
where Tbx3 is over expressed, PTEN protein is decreased (d) with respect to that seen in untransfected cells (c).
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core promoter of PTEN. Both of the PTEN promoter re-
porter plasmids were then transfected into the HeLa and
HEK cell lines either on their own or together with a plas-
mid expressing Tbx3 (Figure 4A). In order to confirmover-expression of Tbx3, western blotting and flow cyto-
metry were performed in parallel. As shown in Figure 4A,
the promoter activity of CP-PTEN was 2-fold stronger
than the EP-PTEN [35,39] and co-transfection of a Tbx3-
expressing plasmid resulted in a 4-fold and a 2- fold
Figure 3 Schematic diagram of PTEN promoter. (A) Core
promoter of PTEN localized between −1345 to −745 is shown. The
beginning of exon 1 is designated as (0) and the start codon “ATG”
within the first exon is indicated. A 1030 bp long leader sequence
(LS) is found between the beginning of the first exon and the ATG
site. The gray area between −958 and −821 is the minimal promoter
of PTEN. Binding sites for the main transcription factors within the
core promoter region are shown. (B) The EP-PTEN, CP-PTEN and Δ
mut. CP-PTEN promoter constructs used in this study are shown. All
promoter regions were cloned into the luciferase expressing plasmid
pGL3 (Luc).
Figure 4 Tbx3 represses PTEN promoter activity. (A) EP-PTEN
and CP-PTEN reporter plasmids were transfected into HeLa and HEK
cell lines with (1μg) or without Tbx3 expressing plasmid. Using a
luminometer, promoter activities of both plasmids were measured
by means of luciferase activity. pGL3 control and pGL3 Basic
plasmids were transfected into both of the cell lines as positive and
negative controls, respectively. In both of the cell lines, expression of
Tbx3 caused 3- to 4-fold reduction in the promoter activities of
EP-PTEN and CP-PTEN reporter plasmids. Over expression of Tbx3
protein upon transfections was confirmed by western blots (WB)
using an antibody against Tbx3 protein. (B) CP-PTEN reporter
plasmid was transfected into both HeLa and HEK cell lines together
with increasing amounts of a Tbx3 expressing plasmid. Promoter
activity of CP-PTEN was then measured via luciferase assays using a
luminometer. The sign “*”denotes for statistically significant decrease
(p<0.05) in the PTEN promoter activity with respect to the basal
activity of CP-PTEN as measured in the absence of Tbx3 expressing
plasmid (100%). Expression of Tbx3 has been demonstrated by
western blots (WB) using an anti-Tbx3 antibody.
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ities, respectively. Importantly, transfection of a Tbx3
expressing plasmid in increasing amounts, which causes
over-expression of Tbx3 within the cells, resulted in pro-
gressive decrease in the PTEN promoter activity
(Figure 4B). In both HeLa and HEK cell lines, a statisti-
cally significant decrease in the basal promoter activity of
CP-PTEN was observed when 0.5 or 1 μg of Tbx3 expres-
sing plasmid was transfected (p<0.05). However, especially
in HeLa cells the CP-PTEN promoter did not exhibit a
linear repression with increasing amounts of transfected
DNA. In correlation with this, western blots did not dem-
onstrate a linear accumulation of Tbx3 protein either. This
could be due to inefficient translation process. In other
words, probably every single transfected DNA molecule
was not successfully translated into protein. Nevertheless,
these results demonstrate that over-expression of Tbx3
within the cells results in repression of PTEN promoter
activity.
The positive acting transcription factor USF has been
demonstrated to bind to a region within the core pro-
moter of PTEN and induce the transcriptional activity of
PTEN promoter [36]. In order to determine whether
Tbx3 would have an effect on induced PTEN promoteractivity, a USF expressing plasmid was transfected into
HeLa and HEK cell lines. As expected, over-expression
of USF caused 1.5-fold increase in the promoter activity
of CP-PTEN (Figure 5). USF also increased the EP-
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shown in Figure 5, when Tbx3 was over-expressed
alongside USF, it was still capable of repressing the
induced transcriptional activity by 2.5- and 3-fold in
HeLa and HEK cell lines, respectively (p<0.05). Thus,
this data demonstrate that Tbx3 represses both the basal
and induced PTEN promoter activity and that this re-
pression is specific as similar patterns of repression was
observed in two different cell lines.
Tbx3 represses PTEN through a 132 bp DNA region
within the PTEN promoter
Since both the EP-PTEN (−1895/+400) and CP-PTEN
(−1477/-710) were repressed by Tbx3, we reasoned that
the DNA region that is responsive to Tbx3 must be
downstream of position −1477. In order to narrow down
the Tbx3-responsive DNA region, we generated a third
plasmid construct spanning between positions −1345 to
−710 (Δ mut-CP-PTEN), in which 132 bp were deleted
downstream of position −1477 (Figure 3A). This was
then transfected into HeLa cells along with the two
other PTEN reporter plasmids, EP-PTEN and CP-PTEN.
As shown in Figure 6, basal activity of Δ mut-CP-PTEN
was weaker compared to EP-PTEN or CP-PTEN, sug-
gesting that the deleted 132 bp contains binding sites for
positive acting factor/s. Interestingly however, although
Tbx3 was capable of repressing EP-PTEN and CP-
PTEN, the deletion mutant was not repressed by Tbx3.
Analysis of this 132 bp DNA region did not reveal the
presence of a canonical Tbx3 binding site. These resultsFigure 5 Tbx3 represses induced PTEN promoter activity. HeLa
and HEK cell lines were transfected with the CP-PTEN reporter
plasmid. Luciferase activity of CP-PTEN was measured in response to
over expressed USF with or without Tbx3. USF is capable of
inducing the transcriptional activity of CP-PTEN by 1.5-fold and Tbx3
is capable of repressing the induced transcription activity by 3-fold
(p<0.05). pGL3 control and pGL3 Basic plasmids were transfected
into both of the cell lines as positive and negative controls,
respectively. The sign “*” denotes for statistically significant
difference in PTEN promoter activity with respect to the basal
activity (100%).suggest that the PTEN promoter region between posi-
tions −1477 to −1345 contains binding sites for possible
positive acting factors and Tbx3 represses PTEN pro-
moter through this particular DNA region.
Discussion
It is now believed that pathways that are critical for
physiological development may also play a role in
tumorigenesis. In support of this, many signalling path-
ways such as Wnt and Notch1 or transcription factors
like Sox2, Tbx2 and Tbx3, all of which are important in
embryologic development, were also shown to be
involved in tumorigenesis [40]. Although Tbx3 exhibits
an abnormal expression pattern in various cancers, mo-
lecular mechanisms underlying the role of Tbx3 in can-
cer are not yet entirely revealed [9-12,14]. Nonetheless,
it is now clear that Tbx3 is one of the major proteins
involved in pathways regulating cellular proliferationFigure 6 A 132 bp DNA region is responsible for repression of
PTEN promoter by Tbx3. 132 bp from the 50-end of CP-PTEN was
deleted to generate the Δ mut. CP-PTEN. All three reporter
constructs were transfected into HeLa cell line and promoter
activities were determined in the absence or presence of 1μg Tbx3
expressing plasmid. As has been shown before, Tbx3 was capable of
repressing promoter activities of both the EP-PTEN and CP-PTEN,
whereas no repression by Tbx3 was detected in Δ mut. CP-PTEN.
Western blot (WB) shown below was performed by an anti-Tbx3
antibody and displays the Tbx3 protein in untransfected and
transfected cells.
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gests that Tbx3 plays an essential part in metastasis
[11,13,41]. This latter role seems to be very important as
success in cancer treatment strategies largely depends
on the capacity of primary tumour cells to metastasize.
In terms of prognosis, squamous cell cancer of head
and neck constitutes one of the worst cancer types, des-
pite advances in diagnostic and treatment strategies. Re-
search towards identifying molecular mechanisms of
HNSCC revealed that many oncogenes and tumour sup-
pressors are involved in formation and progression of
this particular type of cancer. Although these research
allowed establishment of new treatment regimes target-
ing these signalling pathways, the prognosis is still rather
poor due to the aggressive metastatic capacity of this
cancer [42,43]. Metastasis of primary cancer cells to dis-
tant organs is believed to be governed by induction of a
program called epithelial-to-mesenchymal transition
(EMT) [44]. Recently, a microarray analysis performed
on a panel of HNSCC cell lines demonstrated that in
EMT-like HNSCC cell lines Tbx3 was one of the
strongly up-regulated gene besides a set of 145 genes
[45]. Although these results were obtained from cell
lines, nevertheless they are in perfect agreement with
our data presented in this paper which demonstrates
that both the mRNA and protein levels of Tbx3 are
increased in tissues obtained from patients with
HNSCC. Humtsoe et al. [45] also showed that Tbx3
over-expression has resulted in EMT-like cell survival,
while inhibition of Tbx3 by siRNA has suppressed cell
invasion. These results indicate that Tbx3 expression in
HNSCC cell lines induce metastasis and raise the possi-
bility that Tbx3 may be an important diagnostic marker
in HNSCC progression. However, in our study group
neither the clinical stage nor the origin of cancer exhib-
ited a correlation with the Tbx3 mRNA levels. This
could simply be due to the relatively small sample size
and the fact that in our samples the majority of HNSCC
samples originated from larynx (85%) and the patients
were at clinical stage IV (73%) or III (27%). It will be im-
portant to analyze Tbx3 mRNA and protein levels in lar-
ger groups and also in earlier stages of the disease.
Previously several mechanisms have been identified
which Tbx3 uses during cancer formation and progression
[12,16-20]. However, regulation by Tbx3 has not been
demonstrated before for PI3K/PTEN/AKT signalling path-
way, which plays very important roles in cancer formation,
development and cancer cell metabolism. The protein kin-
ase AKT is in the centre of PI3K/PTEN/AKT signalling
pathway and induces cellular proliferation by regulating
protein synthesis, cell metabolism and apoptosis. Activa-
tion of AKT is dependent on enhanced activity of PI3K or
decreased activity of PTEN. Indeed, after p53, PTEN is the
second most altered tumour suppressor in cancers.However, although a reduced expression of PTEN is
observed in most of the solid tumours, genetic mutations
of PTEN are rather rare in most cancer types, except in
glioblastome multiforme and endometrial cancer [46]. In
HNSCC, mutations or amplifications of the genes encod-
ing PI3K or AKT2 have been identified [47-49], but al-
though a reduced protein expression of PTEN has been
reported [27,50-52], rather low rates of mutations (8%)
within the PTEN gene were found [53]. Therefore, one of
the reasons for the loss of PTEN activity or protein ex-
pression observed in HNSCC or other types of cancer
could be through down-regulation of PTEN via transcrip-
tional regulation. The core promoter of PTEN located at
positions −1344 to −745 was found to be capable of gov-
erning the maximum promoter activity [35]. Several stud-
ies performed on PTEN promoter clearly revealed the
presence of negative regulators located both upstream and
downstream of the core promoter, however these regions
were not analyzed further as they were not within the
scope of the respective papers [35,36,39]. In this paper we
demonstrated that Tbx3 is one of the repressors as it was
capable of repressing the transcription activity of PTEN
promoter in both HeLa and HEK cell lines. In addition,
when the PTEN core promoter activity was induced by
over-expressing USF, Tbx3 was again able to overcome the
transcriptional activity and repress the induced PTEN pro-
moter activity. The repression of the induced PTEN pro-
moter activity by Tbx3 could be due to the binding of
Tbx3 and USF to the PTEN promoter simultaneously.
However, it is also entirely possible that over-expressed
Tbx3 could have down-regulated USF expression. Even so,
these results and the fact that increasing amounts of Tbx3
causes a gradual decrease in the promoter activity of
PTEN imply that Tbx3 is capable of repressing PTEN and
that this repression is specific.
How and where within the PTEN promoter Tbx3 binds
to, is not yet clear. Since the deletion mutant (Δ mut CP-
PTEN) was not repressed by Tbx3, it can be argued that
the Tbx3 responsive DNA region within the PTEN pro-
moter is localized between positions −1477 and −1345.
Unfortunately, search for a Tbx3-protein binding site
within this 132 bp region did not reveal a consensus bind-
ing site. However, it is known that although many of the
Tbx-family of proteins bind to brachyury site [54] either
using the whole palindrome or to half-sites only, there can
be some variations within the consensus sequence [55]. It
is also noteworthy to mention that DNA-binding may not
necessarily be an intrinsic determinant for specificity for
Tbx-family of proteins. Indeed, accumulating evidence
indicates that for Tbx family of proteins, DNA target spe-
cificity is dictated by interactions with other transcription
factors and specific chromatin determinants [56-58].
Thus, identification of Tbx3 binding site within the PTEN
promoter or any possible interactions of Tbx3 with the
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further research.
We demonstrated repression of PTEN transcription by
Tbx3, both by using in vitro transcriptional activity
assays and also by quantitative PCR, where we measured
endogenous PTEN mRNA levels in response to over
expressed Tbx3. As has been demonstrated by flow cyto-
metry analyses, over expression of Tbx3 also caused a
reduction in endogenous PTEN protein levels. Although
reductions in endogenous PTEN mRNA and protein
levels in response to over-expressed Tbx3 strongly sug-
gest that this repression may occur in vivo, we were not
able to demonstrate direct binding of Tbx3 to PTEN
promoter in vivo. However, considering that Tbx3 has
been implicated in metastasis of cervix, breast, head and
neck squamous cell carcinomas, as well as melanomas
[11,13,41,45], it is tempting to speculate that this repres-
sion may take place in vivo as well, especially during me-
tastasis. Metastasis is the main cause of death in the
majority of human cancers and in order to survive, can-
cer cells must overcome the challenges that metastatic
processes present, such as apoptosis either due to cellu-
lar detachment or cell shape change [59]. Although re-
sistance to apoptosis enables tumour cells to survive, it
leads to a period of tumour dormancy, as growth in the
metastatic sites is installed temporarily [60]. Anoikis is
the term used to describe apoptosis due to cellular de-
tachment. Role of PTEN in anoikis has been reported
before [61] but direct effect of PTEN on anoikis and
tumour dormancy has been demonstrated in mammary
epithelial cell lines by disruption of PTEN expression
using homologous recombination, which resulted in
growth factor independent proliferation and resistance
to anoikis [62]. Interestingly, in HNSCC cell lines show-
ing EMT-like features in which Tbx3 was found to be
over-expressed, it was also demonstrated that these cell-
lines exhibited resistance to anoikis [45]. Therefore, it is
possible that repression of PTEN by Tbx3 may account
for resistance to anoikis observed in cancer cells.
Conclusions
We have shown that Tbx3 is up-regulated in tissue sam-
ples obtained from patients with HNSCC. In addition,
we demonstrated that Tbx3 is capable of repressing
PTEN transcription. This repression may have implica-
tions in progression and metastasis of cancer cells. In
this scenario, over-expression of Tbx3 may render the
cancer cells to gain the metastatic capacity and by inhi-
biting PTEN, may enable cells to resist apoptosis, there-
fore giving them the chance to survive and migrate to
distant sites.
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